US NUCLEAR CORP.

CIK:0001543623|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Income Statement [Abstract]
Sales	$ 352,209	$ 476,705
Cost of sales	197,214	127,788
Gross profit	154,995	348,917
Operating expenses
Selling, general and administrative expenses	300,898	872,797
Total operating expenses	300,898	872,797
Loss from operations	(145,903)	(523,880)
Other income (expense)
Interest expense	(41,183)	(36,352)
Other income	0
Total other income (expense)	(41,183)	(36,352)
Loss before provision for income taxes	(187,086)	(560,232)
Provision for income taxes
Net loss	(187,086)	(560,232)
Preferred stock dividends	(88,019)	(71,227)
Deemed dividend for down-round provision in warrants
Net loss attributed to common stockholders	$ (275,105)	$ (631,459)
Weighted average shares outstanding - basic (in Shares)	62,701,458	57,309,903
Weighted average shares outstanding - diluted (in Shares)	62,701,458	57,309,903
Loss per shares - basic (in Dollars per share)	$ (0)	$ (0.01)
Loss per shares - diluted (in Dollars per share)	$ 0	$ (0.01)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
OPERATING ACTIVITIES
Net loss	$ (187,086)	$ (560,232)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	524	360
Issuance of common stock for services		56,100
Issuance of warrants for services		394,999
Changes in operating assets and liabilities:
Accounts receivable	130,955	290,413
Note receivable	1,050
Inventory	77,313	(214,107)
Prepaid expenses and other current assets	5,630	10,000
Accounts payable	(90,620)	(3,630)
Accrued liabilities	(30,414)	54,553
Accrued compensation	18,000
Customer deposits	(51,915)	(120,942)
Net cash used in operating activities	(126,563)	(92,486)
FINANCING ACTIVITIES
Net borrowings (repayments) under lines of credit	67,753
Proceeds from issuance of note payable shareholder	5,231	12,000
Proceeds from notes payable	27,000
Repayments of notes payable	(40,882)	(31,865)
Proceeds from issuance of common stock		50,000
Net cash provided by financing activities	59,102	30,135
NET INCREASE (DECREASE) IN CASH	(67,461)	(62,351)
CASH
Beginning of period	134,779	130,840
End of period	67,318	68,489
Supplemental disclosures of cash flow information
Taxes paid
Interest paid	27,285	10,398
Non-cash disclosures:
Common stock issued for conversion of debt and interest		262,046
Preferred stock dividends payable	$ 48,725	$ 41,549

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash	$ 67,318	$ 134,779
Accounts receivable, net	82,745	213,700
Note receivable	38,916	39,966
Inventories, net	1,005,770	1,083,083
Prepaid expenses and other current assets		5,630
TOTAL CURRENT ASSETS	1,194,749	1,477,158
Property and equipment, net		524
Investments	4,539	4,539
Goodwill	439,662	439,662
TOTAL ASSETS	1,638,950	1,921,883
CURRENT LIABILITIES
Accounts payable	126,820	217,440
Accrued liabilities	1,180,201	1,171,321
Accrued compensation - officers	31,000	13,000
Customer deposit	65,581	117,496
Notes payable, current portion	234,580	181,924
Note payable to shareholder	95,561	90,330
Line of credit	452,383	384,630
TOTAL CURRENT LIABILITIES	2,186,126	2,176,141
LONG-TERM LIABILITIES
Notes payable, net of current	117,895	184,433
Convertible notes payable	75,000	75,000
TOTAL LONG-TERM LIABILITIES	192,895	259,433
TOTAL LIABILITIES	2,379,021	2,435,574
COMMITMENTS & CONTINGENCIES
SHAREHOLDERS’ DEFICIT:
Common stock, $0.0001 par value; 100,000,000 shares authorized, 62,822,263 and 62,822,263 shares issued and outstanding	6,283	6,283
Common shares to be issued (593,556 shares)	198,785	150,060
Preferred stock, Series A, $0.0001 par value, 10,000 shares authorized, 2,656 and 2,656, issued and outstanding	266	266
Additional paid in capital	20,478,838	20,478,838
Accumulated deficit	(21,424,243)	(21,149,138)
TOTAL SHAREHOLDERS’ DEFICIT	(740,071)	(513,691)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 1,638,950	$ 1,921,883